# Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

> **NCT03532958** · PHASE2 · WITHDRAWN · sponsor: **Equillium**

## Conditions studied

- Alopecia Areata
- Alopecia Totalis
- Alopecia Universalis

## Interventions

- **DRUG:** BNZ-1
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT03532958
- **Lead sponsor:** Equillium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Transfer of study sponsor
- **Last updated:** 2022-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532958, "Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03532958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*